TABLE 5.
Sr. No. | Bacteriophage | Phage isolation source | Phage efficacy assessment assay | Host range | Antibacterial activity method and result | Country | References |
Phage Rih21 | Hospital Wastewater | Double layer agar method | MRSA | showed lytic activity | Iraq | Ghayyib et al., 2022 | |
Phage cocktail APTC-C-SA01 | Nasal swabs, soil and sheep feces samples | Plaque assay | Biofilm MRSA and MSSA | > 98% lytic activity | Australia | Liu et al., 2022 | |
Phage Henu2 + Antibiotics | Sewage sample | Time kill assay | MRSA, MSSA | Growth decreased faster | China | Li et al., 2021 | |
Phage Sb1 + antibiotics | Commercial purchased | Plague assay and time kill assay | MRSA | Decrease in CFUs after treatment | USA | Kebriaei et al., 2020 | |
Recombinant chimeric bacteriophage endolysin HY-133 | Hypharm GmbH | Broth micro dilution method | MRSA, MSSA, mupirocin-resistant strains | MIC = 0.12–0.5 mg/L, Time kill curve assay showed Bactericidal effect |
Germany | Knaack et al., 2019 | |
Staphylococcal Sb and PYO bacteriophage | Eliava Biopreparations | Microcalori-metry Assay and CFU counting |
MRSA | Rapidly inhibited growth of MRSA in both methods | Germany | Tkhilaishvili et al., 2020 | |
Sb-1 phage | Georgia Eliava Institute | Spot assay | MRSA. MSSA, biofilm | 22/28 MRSA sensitive, 16/29 MSSA sensitive, eradicated biofilm | Germany | Tkhilaishvili et al., 2018 | |
Chimeolysin F (ClyF) | 96-well plate method | S. sureus multiple strains, MRSA, S. pyogenes, S. suis, B cereus | Lytic activity against all S. aureus strains and no against other strains | China | Yang et al., 2017 | ||
pq/27 and pq/48 | Sewage water | Spot assay | MRSA | Agar method + | Pakistan | Rasool et al., 2016 | |
Lysostaphin + L. monocytogenes bacteriophage endolysin-ply511 | N/A | Peptidoglycan hydrolytic activity | MRSA | Agar method High bactericidal activity |
Australia | Turner et al., 2007 |